This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
At the Clinical Trials on Alzheimer's Disease conference in Boston Nov. 16, MIT spinoff company Cognito Therapeutics announced the results of its pivotal clinical trial of a noninvasive, device-based approach to Alzheimer's disease (AD) treatment first discovered in The Picower Institute in 2014. The "HOPE" trial included 663 people in two "prespecified" subgroups of volunteers: those with diagnoses of mild Alzheimer's and those with moderate Alzheimer's.
The 395-member mild group benefited significantly, showing a slowed decline in three standard clinical measures of daily function and cognition relative to untreated controls. Among 169 "protocol-adherent" mild patients who used their devices at least 70% of the intended time, the benefits were more extensive.
The 268-member moderate group did not show clinical benefit, and mild patients did not show statistically significant benefit on some measures. All told, the overall study did not meet its primary endpoint. But based on the significant benefits seen in the mild population, Cognito executives said they would pursue FDA approval for use of their "Spectris" 40Hz light and sound stimulation goggles device (pictured above).
After the 12-month study of 40Hz light and sound stimulation, the mild AD group in the nationwide, randomized, controlled, double-blind trial showed statistically significant benefits on three tests: ADCS-ADL (56% slowed decline), ADCS-iADL (53% slowed decline) and CDR-SB (47% slowed decline), the company said.
The protocol-adherent mild population achieved stronger benefits on those tests (ADCS-ADL: 82%, ADCS-iADL: 82%, CDR-SB: 64%) and reached statistical significance as well on iADMARS (73%).
Source link







